Immune Cell Therapy

Innovative Cellular Therapeutics (ICT) is a clinical-stage biotechnology company focused on developing next-generation chimeric antigen receptor (CAR) T-cell therapies for solid tumors and hematological malignancies. The company utilizes its proprietary CoupledCAR technology platform to overcome the challenges of the tumor microenvironment and enhance the expansion and persistence of CAR-T cells in solid tumors. Its lead candidate, GCC19CART (also known as LYL273), targets guanylate cyclase 2C (GCC) and has demonstrated promising clinical activity in patients with relapsed or refractory metastatic colorectal cancer. ICT operates with a global footprint, maintaining headquarters in Rockville, Maryland, and research facilities in Shanghai, China.